PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.35%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
117.22%
Other expenses change of 117.22% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
89.95%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
89.95%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
-4.24%
Both companies reducing interest expense. Martin Whitman would check industry trends.
100.53%
D&A change of 100.53% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
79.29%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-95.43%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-104.55%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-100.00%
Pre-tax income decline while RVPH shows 5.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.40%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
-134.36%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-134.21%
EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-134.21%
Diluted EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.